Dimpal M. Kasabwala
Dimpal M. Kasabwala has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adel Elkbuli
Department of Surgery, Division of Trauma and Surgical Critical Care, Orlando Regional Medical Center, Orlando, FL, USA
2 shared publications Yusra Othman
2 shared publications- Alexandra Kata1 shared publication
- Amama Ali
Creatv Bio, Division of Creatv MicroTech, Inc., Monmouth Junction, USA
1 shared publication Cha-Mei Tang
Creatv Bio, Inc
1 shared publicationChadwick P. Smith
1 shared publication
Latest Publications
- 30 October 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 328, 293-303
Prevention of Abdominal Compartment Syndrome in Acute Care Surgery: A Scoping Review of Risk Factors and Management Strategies
- 30 October 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 328, 293-303
Prevention of Abdominal Compartment Syndrome in Acute Care Surgery: A Scoping Review of Risk Factors and Management Strategies
- Open Access
- 29 December 2022
- Published by Springer Nature in Research Square
Cancer Associated Macrophage-Like Cells in Metastatic Renal Cell Carcinoma Predicts for Poor Prognosis and Tracks Treatment Response in Real Time
Background Renal Cell Carcinoma (RCC) is a fatal urological cancer, with one third of patients diagnosed with metastasis, resulting in a 5-year survival of only 12%. Recent advancements in therapies have increased survival in mRCC, but lack efficacy in subtypes, due to treatment resistance and toxic side effects. Currently, white blood cells, hemoglobin, and platelets are limitedly used as blood based biomarkers to help determine RCC prognosis. Cancer associated macrophage-like cells (CAMLs) area potential mRCC biomarker which have been identified in peripheral blood of patients with malignant tumors and have been shown to predict poor clinical patient outcomes based on their number and size. Methods In this study, blood samples from 40 RCC patients were obtained to evaluate the clinical utility of CAMLs. CAML changes were monitored during treatment regimens to evaluate their ability to predict treatment efficacy. Results It was observed that patients with smaller CAMLs had better progression free survival (HR=2.84, 95%CI 1.22-6.60, p=0.0273) and overall survival (HR=3.95, 95%CI 1.45-10.78, p=0.0154) versus patients with larger CAMLs. Conclusion These findings suggest that CAMLs can be used as a diagnostic, prognostic, and predictive biomarker for patients with RCC which may help improve management of advanced RCC.
- 29 December 2022
- Published by Springer Nature in Research Square
Open AccessCancer Associated Macrophage-Like Cells in Metastatic Renal Cell Carcinoma Predicts for Poor Prognosis and Tracks Treatment Response in Real Time
Background Renal Cell Carcinoma (RCC) is a fatal urological cancer, with one third of patients diagnosed with metastasis, resulting in a 5-year survival of only 12%. Recent advancements in therapies have increased survival in mRCC, but lack efficacy in subtypes, due to treatment resistance and toxic side effects. Currently, white blood cells, hemoglobin, and platelets are limitedly used as blood based biomarkers to help determine RCC prognosis. Cancer associated macrophage-like cells (CAMLs) area potential mRCC biomarker which have been identified in peripheral blood of patients with malignant tumors and have been shown to predict poor clinical patient outcomes based on their number and size. Methods In this study, blood samples from 40 RCC patients were obtained to evaluate the clinical utility of CAMLs. CAML changes were monitored during treatment regimens to evaluate their ability to predict treatment efficacy. Results It was observed that patients with smaller CAMLs had better progression free survival (HR=2.84, 95%CI 1.22-6.60, p=0.0273) and overall survival (HR=3.95, 95%CI 1.45-10.78, p=0.0154) versus patients with larger CAMLs. Conclusion These findings suggest that CAMLs can be used as a diagnostic, prognostic, and predictive biomarker for patients with RCC which may help improve management of advanced RCC.
- Open Access
- 11 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2898
Micronuclei in Circulating Tumor Associated Macrophages Predicts Progression in Advanced Colorectal Cancer
Micronuclei (MN) are fragments of damaged nucleic acids which budded from a cell’s nuclei as a repair mechanism for chromosomal instabilities, which within circulating white blood cells (cWBCs) signifies increased cancer risk, and in tumor cells indicates aggressive subtypes. MN form overtime and with therapy induction, which requires sequential monitoring of rarer cell subpopulations. We evaluated the peripheral blood (7.5 mL) for MN in Circulating Stromal Cells (CStCs) in a prospective pilot study of advanced colorectal cancer patients (n = 25), identifying MN by DAPI+ structures (p = 0.110) nor stage (p = 0.137). However, presence of MN in CStCs was independently prognostic for PFS (HR = 17.2, 95% CI 3.6–80.9, p = 0.001) and OS (HR = 70.3, 95% CI 6.6–752.8, p = 0.002), indicating a non-interventional mechanism in their formation. Additionally, MN formation did not appear associated with chemotherapy induction, but was correlated with tumor response. MN formation in colorectal cancer is an underlying biological mechanism that appears independent of chemotherapeutic genotoxins, changes during treatment, and predicts for poor clinical outcomes.
- 11 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2898
Open AccessMicronuclei in Circulating Tumor Associated Macrophages Predicts Progression in Advanced Colorectal Cancer
Micronuclei (MN) are fragments of damaged nucleic acids which budded from a cell’s nuclei as a repair mechanism for chromosomal instabilities, which within circulating white blood cells (cWBCs) signifies increased cancer risk, and in tumor cells indicates aggressive subtypes. MN form overtime and with therapy induction, which requires sequential monitoring of rarer cell subpopulations. We evaluated the peripheral blood (7.5 mL) for MN in Circulating Stromal Cells (CStCs) in a prospective pilot study of advanced colorectal cancer patients (n = 25), identifying MN by DAPI+ structures (p = 0.110) nor stage (p = 0.137). However, presence of MN in CStCs was independently prognostic for PFS (HR = 17.2, 95% CI 3.6–80.9, p = 0.001) and OS (HR = 70.3, 95% CI 6.6–752.8, p = 0.002), indicating a non-interventional mechanism in their formation. Additionally, MN formation did not appear associated with chemotherapy induction, but was correlated with tumor response. MN formation in colorectal cancer is an underlying biological mechanism that appears independent of chemotherapeutic genotoxins, changes during treatment, and predicts for poor clinical outcomes.